Prevention of Vein Graft Intimal Hyperplasia with Optimized Human Apyrase

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$281,598.00
Award Year:
2012
Program:
SBIR
Phase:
Phase I
Contract:
1R43HL115860-01
Award Id:
n/a
Agency Tracking Number:
R43HL115860
Solicitation Year:
2012
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA11-096
Small Business Information
4041 Forest Park Avenue, SAINT LOUIS, MO, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
192266141
Principal Investigator:
RIDONGCHEN
(312) 339-8455
rchen@apt-therapeutics.com
Business Contact:
RIDONGCHEN
(312) 339-8455
rchen@apt-therapeutics.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): The saphenous vein is the most commonly used graft for coronary artery bypass and peripheral bypass surgery, but has poor patency. 15-20% grafts fail in the first month and approximately 25% in the first year. Early vein graft occlusion is typically due to thrombosis, while late failures typically result from neointimal hyperplasia, a pathological adaptation process that occurs in veins exposed to the arterial circulation. Recent decades have seen the development of manynew therapeutic agents to try to improve vein graft patency, but none has translated into clinical utility. Consequently, the problem of neointimal hyperplasia continues to remain unacceptable to patients and clinicians alike. APT102 is an optimized humanenzyme that hydrolyzes extracellular prothrombotic ADP and proinflammatory ATP and ultimately leads to generation of anti- inflammatory adenosine in vivo. The goal of this Phase I SBIR grant application is to determine the long-term anti-neointimal effects of APT102 in the setting of vein graft surgery in mice. The ultimate goal is to develop apyrase-based therapy as the standard of care therapy for coronary and peripheral bypass surgery patients. PUBLIC HEALTH RELEVANCE: The goal of this Phase ISBIR grant application is to determine the long-term anti- neointimal effects of an optimized human apyrase in the setting of vein graft surgery in mice. The ultimate goal is to develop apyrase-based therapy as the standard of care therapy for coronary andperipheral bypass surgery patients.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government